Blue Jet Healthcare Limited (IN:BLUEJET)
:BLUEJET
Want to see IN:BLUEJET full AI Analyst Report?
Top Page
Blue Jet Healthcare Limited
(BLUEJET)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹478.00
▼(-26.85% Downside)
Action:Reiterated
Date:05/26/26
The score is driven primarily by strong financial quality (high profitability and a very low-debt balance sheet), tempered by a sharp FY2026 revenue decline and inconsistent cash/FCF conversion. Technically, the setup is mildly constructive but not fully repaired versus the 200-day trend. Valuation is the biggest drag due to the high P/E and minimal dividend yield.
Positive Factors
Conservative balance sheet with very low leverage
Extremely low debt and a steadily expanding equity base give the company durable financial flexibility. This conservatism reduces solvency risk, supports investment or acquisitions without refinancing pressure, and cushions operations through industry cycles over the next 2–6 months.
Negative Factors
Sharp FY2026 revenue decline and choppy growth profile
A near-20% top-line drop in FY2026 signals meaningful demand, mix or execution issues that can persist across quarters. For a specialized API maker, sustained revenue weakness reduces leverage from fixed-cost base, pressures margins and limits reinvestment capacity over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet with very low leverage
Extremely low debt and a steadily expanding equity base give the company durable financial flexibility. This conservatism reduces solvency risk, supports investment or acquisitions without refinancing pressure, and cushions operations through industry cycles over the next 2–6 months.
Read all positive factors
Blue Jet Healthcare Limited (BLUEJET) vs. iShares MSCI India ETF (INDA)
Market Cap
₹88.93B
Dividend Yield0.22%
Average Volume (3M)19.19K
Price to Earnings (P/E)35.8
Beta (1Y)1.39
Revenue Growth-8.03%
EPS Growth-18.80%
CountryIN
Employees447
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)20.33
Shares Outstanding173,465,420
10 Day Avg. Volume15,409
30 Day Avg. Volume19,187
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)4.17
Price to Sales (P/S)5.99
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹370.00Price Target Upside-43.38% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)18.33
Revenue Forecast (FY)₹11.97B
Blue Jet Healthcare Limited Business Overview & Revenue Model
Company Description
Blue Jet Healthcare Ltd. is a company that focuses on the manufacturing and supply of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), which are critical components for the pharmaceutical and healthcare sectors. Its produ...
How the Company Makes Money
Blue Jet Healthcare Limited makes money mainly by manufacturing and selling pharmaceutical APIs and intermediates to customers in the pharmaceutical value chain. Revenue is generated through (i) product sales of APIs and intermediates, typically s...
Blue Jet Healthcare Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
91
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.79B | 9.47B | 10.30B | 7.10B | 7.18B | 6.77B |
| Gross Profit | 6.16B | 4.14B | 5.69B | 3.89B | 2.70B | 2.97B |
| EBITDA | 4.85B | 2.94B | 4.24B | 2.48B | 2.43B | 2.69B |
| Net Income | 3.52B | 2.48B | 3.05B | 1.64B | 1.60B | 1.82B |
Balance Sheet | ||||||
| Total Assets | 15.27B | 16.41B | 14.18B | 10.59B | 8.62B | 7.13B |
| Cash, Cash Equivalents and Short-Term Investments | 4.11B | 3.76B | 3.06B | 3.09B | 2.55B | 1.81B |
| Total Debt | 206.29M | 421.84M | 199.86M | 16.13M | 68.31M | 228.39M |
| Total Liabilities | 2.72B | 2.81B | 2.84B | 2.14B | 1.81B | 1.92B |
| Stockholders Equity | 12.56B | 13.60B | 11.33B | 8.45B | 6.81B | 5.22B |
Cash Flow | ||||||
| Free Cash Flow | 817.22M | 0.00 | -341.15M | 669.59M | 822.79M | 1.21B |
| Operating Cash Flow | 2.07B | 3.38B | 457.65M | 2.41B | 1.42B | 1.46B |
| Investing Cash Flow | -1.65B | -2.84B | -351.83M | -2.64B | -1.47B | -760.26M |
| Financing Cash Flow | -85.36M | -259.95M | -185.57M | -19.86M | -42.33M | -561.45M |
Blue Jet Healthcare Limited Technical Analysis
Positive
653.45
Price Trends
452.41
Positive
420.08
Positive
513.00
Negative
Market Momentum
17.91
Negative
63.22
Neutral
77.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Positive. The current price of 653.45 is above the 20-day moving average (MA) of 478.61, above the 50-day MA of 452.41, and above the 200-day MA of 513.00, indicating a neutral trend. The MACD of 17.91 indicates Negative momentum. The RSI at 63.22 is Neutral, neither overbought nor oversold. The STOCH value of 77.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLUEJET.
Blue Jet Healthcare Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹74.94B | 35.89 | ― | 0.13% | 18.86% | 11.25% | |
68 Neutral | ₹137.73B | 54.31 | ― | 0.80% | -12.10% | -29.87% | |
64 Neutral | ₹88.93B | 35.76 | ― | 0.22% | -8.03% | -18.80% | |
56 Neutral | ₹673.16B | 171.04 | ― | 0.12% | 10.91% | -67.33% | |
56 Neutral | ₹101.63B | 36.73 | ― | 0.74% | 5.04% | 11.10% | |
56 Neutral | ₹177.98B | 55.88 | ― | 0.19% | 2.64% | -36.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:BLUEJET
Blue Jet Healthcare Limited
512.65
-340.55
-39.91%
IN:BIOCON
Biocon Limited
415.70
64.07
18.22%
IN:CONCORDBIO
Concord Biotech Ltd.
1,316.55
-494.42
-27.30%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
638.05
-81.76
-11.36%
IN:SUPRIYA
Supriya Lifescience Limited
931.10
259.27
38.59%
IN:SYNGENE
Syngene International Ltd.
440.90
-193.17
-30.47%
Blue Jet Healthcare Limited Corporate Events
Blue Jet Healthcare posts FY26 earnings call transcript for investors
May 29, 2026
Blue Jet Healthcare Limited has released the transcript of its earnings call with analysts and investors discussing financial results for the quarter and full year ended March 31, 2026. The document, held on May 25, 2026 and now available on the c...
Blue Jet Healthcare Clears FY26 Results, Dividend and Rs 10 Billion Fund-Raise Plan
May 25, 2026
Blue Jet Healthcare’s board has approved the audited standalone financial results for the quarter and year ended 31 March 2026, with the statutory auditors issuing an unmodified opinion, underscoring the reliability of its reported performan...
Blue Jet Healthcare Clears FY26 Results, Dividend and ₹10 Billion Fundraise Plan
May 25, 2026
Blue Jet Healthcare’s board has approved the audited standalone financial results for the quarter and year ended 31 March 2026, with statutory auditors issuing an unmodified opinion, underscoring the company’s clean financial reporting...
Blue Jet Healthcare Clears FY26 Results, Dividend and Rs 10 Billion Fund-Raising Plan
May 25, 2026
Blue Jet Healthcare’s board has approved the audited standalone financial results for the quarter and year ended 31 March 2026, with statutory auditors KKC Associates LLP issuing an unmodified opinion, underscoring the company’s clean...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.